ERS16296845 SAMEA114307843 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 1 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 1 scientific_name Homo sapiens ERS16296846 SAMEA114307844 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 10 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 10 scientific_name Homo sapiens ERS16296847 SAMEA114307845 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 100 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 100 scientific_name Homo sapiens ERS16296848 SAMEA114307846 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 101 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 101 scientific_name Homo sapiens ERS16296849 SAMEA114307847 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 102 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 102 scientific_name Homo sapiens ERS16296850 SAMEA114307848 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 103 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 103 scientific_name Homo sapiens ERS16296851 SAMEA114307849 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 104 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 104 scientific_name Homo sapiens ERS16296852 SAMEA114307850 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 105 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 105 scientific_name Homo sapiens ERS16296853 SAMEA114307851 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 106 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 106 scientific_name Homo sapiens ERS16296854 SAMEA114307852 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 107 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 107 scientific_name Homo sapiens ERS16296855 SAMEA114307853 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 108 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 108 scientific_name Homo sapiens ERS16296856 SAMEA114307854 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 109 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 109 scientific_name Homo sapiens ERS16296857 SAMEA114307855 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 11 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 11 scientific_name Homo sapiens ERS16296858 SAMEA114307856 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 110 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 110 scientific_name Homo sapiens ERS16296859 SAMEA114307857 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 111 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 111 scientific_name Homo sapiens ERS16296860 SAMEA114307858 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 112 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 112 scientific_name Homo sapiens ERS16296861 SAMEA114307859 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 113 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 113 scientific_name Homo sapiens ERS16296862 SAMEA114307860 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 114 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 114 scientific_name Homo sapiens ERS16296863 SAMEA114307861 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 115 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 115 scientific_name Homo sapiens ERS16296864 SAMEA114307862 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 116 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 116 scientific_name Homo sapiens ERS16296865 SAMEA114307863 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 117 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 117 scientific_name Homo sapiens ERS16296866 SAMEA114307864 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 118 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 118 scientific_name Homo sapiens ERS16296867 SAMEA114307865 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 119 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 119 scientific_name Homo sapiens ERS16296868 SAMEA114307866 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 12 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 12 scientific_name Homo sapiens ERS16296869 SAMEA114307867 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 120 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 120 scientific_name Homo sapiens ERS16296870 SAMEA114307868 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 121 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 121 scientific_name Homo sapiens ERS16296871 SAMEA114307869 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 122 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 122 scientific_name Homo sapiens ERS16296872 SAMEA114307870 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 123 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 123 scientific_name Homo sapiens ERS16296873 SAMEA114307871 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 124 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 124 scientific_name Homo sapiens ERS16296874 SAMEA114307872 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 125 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 125 scientific_name Homo sapiens ERS16296875 SAMEA114307873 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 126 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 126 scientific_name Homo sapiens ERS16296876 SAMEA114307874 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 127 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 127 scientific_name Homo sapiens ERS16296877 SAMEA114307875 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 128 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 128 scientific_name Homo sapiens ERS16296878 SAMEA114307876 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 129 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 129 scientific_name Homo sapiens ERS16296879 SAMEA114307877 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 13 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 13 scientific_name Homo sapiens ERS16296880 SAMEA114307878 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 130 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 130 scientific_name Homo sapiens ERS16296881 SAMEA114307879 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 131 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 131 scientific_name Homo sapiens ERS16296882 SAMEA114307880 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 132 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 132 scientific_name Homo sapiens ERS16296883 SAMEA114307881 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 133 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 133 scientific_name Homo sapiens ERS16296884 SAMEA114307882 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 134 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 134 scientific_name Homo sapiens ERS16296885 SAMEA114307883 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 135 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 135 scientific_name Homo sapiens ERS16296886 SAMEA114307884 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 136 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 136 scientific_name Homo sapiens ERS16296887 SAMEA114307885 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 137 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 137 scientific_name Homo sapiens ERS16296888 SAMEA114307886 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 138 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 138 scientific_name Homo sapiens ERS16296889 SAMEA114307887 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 139 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 139 scientific_name Homo sapiens ERS16296890 SAMEA114307888 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 14 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 14 scientific_name Homo sapiens ERS16296891 SAMEA114307889 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 140 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 140 scientific_name Homo sapiens ERS16296892 SAMEA114307890 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 141 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 141 scientific_name Homo sapiens ERS16296893 SAMEA114307891 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 142 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 142 scientific_name Homo sapiens ERS16296894 SAMEA114307892 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 143 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 143 scientific_name Homo sapiens ERS16296895 SAMEA114307893 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 144 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 144 scientific_name Homo sapiens ERS16296896 SAMEA114307894 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 145 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 145 scientific_name Homo sapiens ERS16296897 SAMEA114307895 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 146 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 146 scientific_name Homo sapiens ERS16296898 SAMEA114307896 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 147 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 147 scientific_name Homo sapiens ERS16296899 SAMEA114307897 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 148 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 148 scientific_name Homo sapiens ERS16296900 SAMEA114307898 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 149 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 149 scientific_name Homo sapiens ERS16296901 SAMEA114307899 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 15 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 15 scientific_name Homo sapiens ERS16296902 SAMEA114307900 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 150 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 150 scientific_name Homo sapiens ERS16296903 SAMEA114307901 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 151 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 151 scientific_name Homo sapiens ERS16296904 SAMEA114307902 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 152 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 152 scientific_name Homo sapiens ERS16296905 SAMEA114307903 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 153 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 153 scientific_name Homo sapiens ERS16296906 SAMEA114307904 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 154 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 154 scientific_name Homo sapiens ERS16296907 SAMEA114307905 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 155 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 155 scientific_name Homo sapiens ERS16296908 SAMEA114307906 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 156 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 156 scientific_name Homo sapiens ERS16296909 SAMEA114307907 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 157 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 157 scientific_name Homo sapiens ERS16296910 SAMEA114307908 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 158 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 158 scientific_name Homo sapiens ERS16296911 SAMEA114307909 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 159 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 159 scientific_name Homo sapiens ERS16296912 SAMEA114307910 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 16 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 16 scientific_name Homo sapiens ERS16296913 SAMEA114307911 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 160 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 160 scientific_name Homo sapiens ERS16296914 SAMEA114307912 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 161 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 161 scientific_name Homo sapiens ERS16296915 SAMEA114307913 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 162 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 162 scientific_name Homo sapiens ERS16296916 SAMEA114307914 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 163 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 163 scientific_name Homo sapiens ERS16296917 SAMEA114307915 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 164 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 164 scientific_name Homo sapiens ERS16296918 SAMEA114307916 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 165 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 165 scientific_name Homo sapiens ERS16296919 SAMEA114307917 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 166 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 166 scientific_name Homo sapiens ERS16296920 SAMEA114307918 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 167 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 167 scientific_name Homo sapiens ERS16296921 SAMEA114307919 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 168 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 168 scientific_name Homo sapiens ERS16296922 SAMEA114307920 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 169 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 169 scientific_name Homo sapiens ERS16296923 SAMEA114307921 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 17 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 17 scientific_name Homo sapiens ERS16296924 SAMEA114307922 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 170 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 170 scientific_name Homo sapiens ERS16296925 SAMEA114307923 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 171 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 171 scientific_name Homo sapiens ERS16296926 SAMEA114307924 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 172 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 172 scientific_name Homo sapiens ERS16296927 SAMEA114307925 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 173 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 173 scientific_name Homo sapiens ERS16296928 SAMEA114307926 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 174 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 174 scientific_name Homo sapiens ERS16296929 SAMEA114307927 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 175 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 175 scientific_name Homo sapiens ERS16296930 SAMEA114307928 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 176 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 176 scientific_name Homo sapiens ERS16296931 SAMEA114307929 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 177 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 177 scientific_name Homo sapiens ERS16296932 SAMEA114307930 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 178 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 178 scientific_name Homo sapiens ERS16296933 SAMEA114307931 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 179 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 179 scientific_name Homo sapiens ERS16296934 SAMEA114307932 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 18 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 18 scientific_name Homo sapiens ERS16296935 SAMEA114307933 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 180 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 180 scientific_name Homo sapiens ERS16296936 SAMEA114307934 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 181 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 181 scientific_name Homo sapiens ERS16296937 SAMEA114307935 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 182 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 182 scientific_name Homo sapiens ERS16296938 SAMEA114307936 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 183 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 183 scientific_name Homo sapiens ERS16296939 SAMEA114307937 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 184 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 184 scientific_name Homo sapiens ERS16296940 SAMEA114307938 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 185 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 185 scientific_name Homo sapiens ERS16296941 SAMEA114307939 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 186 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 186 scientific_name Homo sapiens ERS16296942 SAMEA114307940 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 187 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 187 scientific_name Homo sapiens ERS16296943 SAMEA114307941 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 188 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 188 scientific_name Homo sapiens ERS16296944 SAMEA114307942 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 189 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 189 scientific_name Homo sapiens ERS16296945 SAMEA114307943 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 19 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 19 scientific_name Homo sapiens ERS16296946 SAMEA114307944 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 190 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 190 scientific_name Homo sapiens ERS16296947 SAMEA114307945 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 191 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 191 scientific_name Homo sapiens ERS16296948 SAMEA114307946 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 192 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 192 scientific_name Homo sapiens ERS16296949 SAMEA114307947 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 193 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 193 scientific_name Homo sapiens ERS16296950 SAMEA114307948 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 194 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 194 scientific_name Homo sapiens ERS16296951 SAMEA114307949 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 195 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 195 scientific_name Homo sapiens ERS16296952 SAMEA114307950 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 196 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 196 scientific_name Homo sapiens ERS16296953 SAMEA114307951 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 197 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 197 scientific_name Homo sapiens ERS16296954 SAMEA114307952 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 198 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 198 scientific_name Homo sapiens ERS16296955 SAMEA114307953 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 199 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 199 scientific_name Homo sapiens ERS16296956 SAMEA114307954 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 2 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 2 scientific_name Homo sapiens ERS16296957 SAMEA114307955 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 20 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 20 scientific_name Homo sapiens ERS16296958 SAMEA114307956 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 200 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 200 scientific_name Homo sapiens ERS16296959 SAMEA114307957 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 201 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 201 scientific_name Homo sapiens ERS16296960 SAMEA114307958 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 202 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 202 scientific_name Homo sapiens ERS16296961 SAMEA114307959 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 203 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 203 scientific_name Homo sapiens ERS16296962 SAMEA114307960 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 204 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 204 scientific_name Homo sapiens ERS16296963 SAMEA114307961 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 205 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 205 scientific_name Homo sapiens ERS16296964 SAMEA114307962 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 206 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 206 scientific_name Homo sapiens ERS16296965 SAMEA114307963 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 207 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 207 scientific_name Homo sapiens ERS16296966 SAMEA114307964 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 208 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 208 scientific_name Homo sapiens ERS16296967 SAMEA114307965 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 209 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 209 scientific_name Homo sapiens ERS16296968 SAMEA114307966 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 21 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 21 scientific_name Homo sapiens ERS16296969 SAMEA114307967 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 210 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 210 scientific_name Homo sapiens ERS16296970 SAMEA114307968 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 211 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 211 scientific_name Homo sapiens ERS16296971 SAMEA114307969 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 212 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 212 scientific_name Homo sapiens ERS16296972 SAMEA114307970 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 213 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 213 scientific_name Homo sapiens ERS16296973 SAMEA114307971 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 214 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 214 scientific_name Homo sapiens ERS16296974 SAMEA114307972 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 215 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 215 scientific_name Homo sapiens ERS16296975 SAMEA114307973 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 216 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 216 scientific_name Homo sapiens ERS16296976 SAMEA114307974 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 217 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 217 scientific_name Homo sapiens ERS16296977 SAMEA114307975 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 218 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 218 scientific_name Homo sapiens ERS16296978 SAMEA114307976 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 219 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 219 scientific_name Homo sapiens ERS16296979 SAMEA114307977 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 22 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 22 scientific_name Homo sapiens ERS16296980 SAMEA114307978 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 220 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 220 scientific_name Homo sapiens ERS16296981 SAMEA114307979 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 221 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 221 scientific_name Homo sapiens ERS16296982 SAMEA114307980 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 222 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 222 scientific_name Homo sapiens ERS16296983 SAMEA114307981 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 223 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 223 scientific_name Homo sapiens ERS16296984 SAMEA114307982 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 224 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 224 scientific_name Homo sapiens ERS16296985 SAMEA114307983 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 225 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 225 scientific_name Homo sapiens ERS16296986 SAMEA114307984 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 226 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 226 scientific_name Homo sapiens ERS16296987 SAMEA114307985 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 227 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 227 scientific_name Homo sapiens ERS16296988 SAMEA114307986 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 228 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 228 scientific_name Homo sapiens ERS16296989 SAMEA114307987 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 229 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 229 scientific_name Homo sapiens ERS16296990 SAMEA114307988 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 23 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 23 scientific_name Homo sapiens ERS16296991 SAMEA114307989 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 230 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 230 scientific_name Homo sapiens ERS16296992 SAMEA114307990 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 231 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 231 scientific_name Homo sapiens ERS16296993 SAMEA114307991 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 232 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 232 scientific_name Homo sapiens ERS16296994 SAMEA114307992 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 233 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 233 scientific_name Homo sapiens ERS16296995 SAMEA114307993 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 234 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 234 scientific_name Homo sapiens ERS16296996 SAMEA114307994 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 235 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 235 scientific_name Homo sapiens ERS16296997 SAMEA114307995 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 236 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 236 scientific_name Homo sapiens ERS16296998 SAMEA114307996 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 237 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 237 scientific_name Homo sapiens ERS16296999 SAMEA114307997 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 238 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 238 scientific_name Homo sapiens ERS16297000 SAMEA114307998 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 239 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 239 scientific_name Homo sapiens ERS16297001 SAMEA114307999 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 24 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 24 scientific_name Homo sapiens ERS16297002 SAMEA114308000 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 240 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 240 scientific_name Homo sapiens ERS16297003 SAMEA114308001 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 241 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 241 scientific_name Homo sapiens ERS16297004 SAMEA114308002 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 242 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 242 scientific_name Homo sapiens ERS16297005 SAMEA114308003 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 243 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 243 scientific_name Homo sapiens ERS16297006 SAMEA114308004 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 244 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 244 scientific_name Homo sapiens ERS16297007 SAMEA114308005 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 245 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 245 scientific_name Homo sapiens ERS16297008 SAMEA114308006 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 246 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 246 scientific_name Homo sapiens ERS16297009 SAMEA114308007 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 247 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 247 scientific_name Homo sapiens ERS16297010 SAMEA114308008 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 248 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 248 scientific_name Homo sapiens ERS16297011 SAMEA114308009 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 249 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 249 scientific_name Homo sapiens ERS16297012 SAMEA114308010 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 25 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 25 scientific_name Homo sapiens ERS16297014 SAMEA114308012 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 251 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 251 scientific_name Homo sapiens ERS16297015 SAMEA114308013 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 252 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 252 scientific_name Homo sapiens ERS16297016 SAMEA114308014 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 253 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 253 scientific_name Homo sapiens ERS16297017 SAMEA114308015 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 254 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 254 scientific_name Homo sapiens ERS16297018 SAMEA114308016 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 255 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 255 scientific_name Homo sapiens ERS16297019 SAMEA114308017 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 256 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 256 scientific_name Homo sapiens ERS16297020 SAMEA114308018 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 257 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 257 scientific_name Homo sapiens ERS16297021 SAMEA114308019 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 258 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 258 scientific_name Homo sapiens ERS16297022 SAMEA114308020 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 259 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 259 scientific_name Homo sapiens ERS16297023 SAMEA114308021 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 26 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 26 scientific_name Homo sapiens ERS16297024 SAMEA114308022 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 260 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 260 scientific_name Homo sapiens ERS16297013 SAMEA114308011 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 250 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 250 scientific_name Homo sapiens ERS16297025 SAMEA114308023 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 261 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 261 scientific_name Homo sapiens ERS16297026 SAMEA114308024 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 262 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 262 scientific_name Homo sapiens ERS16297027 SAMEA114308025 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 263 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 263 scientific_name Homo sapiens ERS16297028 SAMEA114308026 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 264 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 264 scientific_name Homo sapiens ERS16297029 SAMEA114308027 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 265 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 265 scientific_name Homo sapiens ERS16297030 SAMEA114308028 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 266 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 266 scientific_name Homo sapiens ERS16297031 SAMEA114308029 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 267 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 267 scientific_name Homo sapiens ERS16297032 SAMEA114308030 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 268 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 268 scientific_name Homo sapiens ERS16297033 SAMEA114308031 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 269 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 269 scientific_name Homo sapiens ERS16297034 SAMEA114308032 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 27 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 27 scientific_name Homo sapiens ERS16297035 SAMEA114308033 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 270 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 270 scientific_name Homo sapiens ERS16297036 SAMEA114308034 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 271 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 271 scientific_name Homo sapiens ERS16297037 SAMEA114308035 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 272 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 272 scientific_name Homo sapiens ERS16297038 SAMEA114308036 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 273 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 273 scientific_name Homo sapiens ERS16297039 SAMEA114308037 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 274 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 274 scientific_name Homo sapiens ERS16297040 SAMEA114308038 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 275 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 275 scientific_name Homo sapiens ERS16297041 SAMEA114308039 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 276 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 276 scientific_name Homo sapiens ERS16297042 SAMEA114308040 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 277 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 277 scientific_name Homo sapiens ERS16297043 SAMEA114308041 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 278 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 278 scientific_name Homo sapiens ERS16297044 SAMEA114308042 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 279 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 279 scientific_name Homo sapiens ERS16297045 SAMEA114308043 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 28 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 28 scientific_name Homo sapiens ERS16297046 SAMEA114308044 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 280 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 280 scientific_name Homo sapiens ERS16297047 SAMEA114308045 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 281 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 281 scientific_name Homo sapiens ERS16297048 SAMEA114308046 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 282 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 282 scientific_name Homo sapiens ERS16297049 SAMEA114308047 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 283 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 283 scientific_name Homo sapiens ERS16297050 SAMEA114308048 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 284 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 284 scientific_name Homo sapiens ERS16297051 SAMEA114308049 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 285 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 285 scientific_name Homo sapiens ERS16297052 SAMEA114308050 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 286 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 286 scientific_name Homo sapiens ERS16297053 SAMEA114308051 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 287 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 287 scientific_name Homo sapiens ERS16297054 SAMEA114308052 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 288 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 288 scientific_name Homo sapiens ERS16297055 SAMEA114308053 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 289 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 289 scientific_name Homo sapiens ERS16297056 SAMEA114308054 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 29 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 29 scientific_name Homo sapiens ERS16297057 SAMEA114308055 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 290 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 290 scientific_name Homo sapiens ERS16297058 SAMEA114308056 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 291 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 291 scientific_name Homo sapiens ERS16297059 SAMEA114308057 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 292 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 292 scientific_name Homo sapiens ERS16297060 SAMEA114308058 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 293 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 293 scientific_name Homo sapiens ERS16297061 SAMEA114308059 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 294 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 294 scientific_name Homo sapiens ERS16297062 SAMEA114308060 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 295 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 295 scientific_name Homo sapiens ERS16297063 SAMEA114308061 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 296 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 296 scientific_name Homo sapiens ERS16297064 SAMEA114308062 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 297 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 297 scientific_name Homo sapiens ERS16297065 SAMEA114308063 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 298 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 298 scientific_name Homo sapiens ERS16297066 SAMEA114308064 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 299 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 299 scientific_name Homo sapiens ERS16297067 SAMEA114308065 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 3 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 3 scientific_name Homo sapiens ERS16297068 SAMEA114308066 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 30 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 30 scientific_name Homo sapiens ERS16297069 SAMEA114308067 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 300 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 300 scientific_name Homo sapiens ERS16297070 SAMEA114308068 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 301 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 301 scientific_name Homo sapiens ERS16297071 SAMEA114308069 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 302 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 302 scientific_name Homo sapiens ERS16297072 SAMEA114308070 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 303 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 303 scientific_name Homo sapiens ERS16297073 SAMEA114308071 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 304 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 304 scientific_name Homo sapiens ERS16297074 SAMEA114308072 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 305 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 305 scientific_name Homo sapiens ERS16297075 SAMEA114308073 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 306 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 306 scientific_name Homo sapiens ERS16297076 SAMEA114308074 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 307 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 307 scientific_name Homo sapiens ERS16297077 SAMEA114308075 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 308 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 308 scientific_name Homo sapiens ERS16297078 SAMEA114308076 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 309 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 309 scientific_name Homo sapiens ERS16297079 SAMEA114308077 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 31 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 31 scientific_name Homo sapiens ERS16297080 SAMEA114308078 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 310 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 310 scientific_name Homo sapiens ERS16297081 SAMEA114308079 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 311 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 311 scientific_name Homo sapiens ERS16297082 SAMEA114308080 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 312 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 312 scientific_name Homo sapiens ERS16297083 SAMEA114308081 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 313 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 313 scientific_name Homo sapiens ERS16297084 SAMEA114308082 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 314 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 314 scientific_name Homo sapiens ERS16297085 SAMEA114308083 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 315 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 315 scientific_name Homo sapiens ERS16297086 SAMEA114308084 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 316 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 316 scientific_name Homo sapiens ERS16297087 SAMEA114308085 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 317 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 317 scientific_name Homo sapiens ERS16297088 SAMEA114308086 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 318 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 318 scientific_name Homo sapiens ERS16297089 SAMEA114308087 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 319 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 319 scientific_name Homo sapiens ERS16297090 SAMEA114308088 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 32 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 32 scientific_name Homo sapiens ERS16297091 SAMEA114308089 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 320 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 320 scientific_name Homo sapiens ERS16297092 SAMEA114308090 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 321 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 321 scientific_name Homo sapiens ERS16297093 SAMEA114308091 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 322 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 322 scientific_name Homo sapiens ERS16297094 SAMEA114308092 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 323 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 323 scientific_name Homo sapiens ERS16297095 SAMEA114308093 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 324 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 324 scientific_name Homo sapiens ERS16297096 SAMEA114308094 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 325 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 325 scientific_name Homo sapiens ERS16297097 SAMEA114308095 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 326 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 326 scientific_name Homo sapiens ERS16297098 SAMEA114308096 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 327 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 327 scientific_name Homo sapiens ERS16297099 SAMEA114308097 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 328 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 328 scientific_name Homo sapiens ERS16297100 SAMEA114308098 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 329 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 329 scientific_name Homo sapiens ERS16297101 SAMEA114308099 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 33 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 33 scientific_name Homo sapiens ERS16297102 SAMEA114308100 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 330 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 330 scientific_name Homo sapiens ERS16297103 SAMEA114308101 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 331 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 331 scientific_name Homo sapiens ERS16297104 SAMEA114308102 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 332 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 332 scientific_name Homo sapiens ERS16297105 SAMEA114308103 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 333 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 333 scientific_name Homo sapiens ERS16297106 SAMEA114308104 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 334 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 334 scientific_name Homo sapiens ERS16297107 SAMEA114308105 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 335 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 335 scientific_name Homo sapiens ERS16297108 SAMEA114308106 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 336 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 336 scientific_name Homo sapiens ERS16297109 SAMEA114308107 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 337 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 337 scientific_name Homo sapiens ERS16297110 SAMEA114308108 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 338 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 338 scientific_name Homo sapiens ERS16297111 SAMEA114308109 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 339 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 339 scientific_name Homo sapiens ERS16297112 SAMEA114308110 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 34 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 34 scientific_name Homo sapiens ERS16297113 SAMEA114308111 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 340 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 340 scientific_name Homo sapiens ERS16297114 SAMEA114308112 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 341 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 341 scientific_name Homo sapiens ERS16297115 SAMEA114308113 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 342 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 342 scientific_name Homo sapiens ERS16297116 SAMEA114308114 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 343 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 343 scientific_name Homo sapiens ERS16297117 SAMEA114308115 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 344 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 344 scientific_name Homo sapiens ERS16297118 SAMEA114308116 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 345 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 345 scientific_name Homo sapiens ERS16297119 SAMEA114308117 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 346 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 346 scientific_name Homo sapiens ERS16297120 SAMEA114308118 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 347 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 347 scientific_name Homo sapiens ERS16297121 SAMEA114308119 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 348 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 348 scientific_name Homo sapiens ERS16297122 SAMEA114308120 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 349 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 349 scientific_name Homo sapiens ERS16297123 SAMEA114308121 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 35 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 35 scientific_name Homo sapiens ERS16297124 SAMEA114308122 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 350 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 350 scientific_name Homo sapiens ERS16297125 SAMEA114308123 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 351 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 351 scientific_name Homo sapiens ERS16297126 SAMEA114308124 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 352 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 352 scientific_name Homo sapiens ERS16297127 SAMEA114308125 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 353 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 353 scientific_name Homo sapiens ERS16297128 SAMEA114308126 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 354 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 354 scientific_name Homo sapiens ERS16297129 SAMEA114308127 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 355 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 355 scientific_name Homo sapiens ERS16297130 SAMEA114308128 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 356 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 356 scientific_name Homo sapiens ERS16297131 SAMEA114308129 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 357 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 357 scientific_name Homo sapiens ERS16297132 SAMEA114308130 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 358 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 358 scientific_name Homo sapiens ERS16297133 SAMEA114308131 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 359 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 359 scientific_name Homo sapiens ERS16297134 SAMEA114308132 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 36 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 36 scientific_name Homo sapiens ERS16297135 SAMEA114308133 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 360 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 360 scientific_name Homo sapiens ERS16297136 SAMEA114308134 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 361 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 361 scientific_name Homo sapiens ERS16297137 SAMEA114308135 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 362 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 362 scientific_name Homo sapiens ERS16297138 SAMEA114308136 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 363 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 363 scientific_name Homo sapiens ERS16297139 SAMEA114308137 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 364 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 364 scientific_name Homo sapiens ERS16297140 SAMEA114308138 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 365 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 365 scientific_name Homo sapiens ERS16297141 SAMEA114308139 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 366 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 366 scientific_name Homo sapiens ERS16297142 SAMEA114308140 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 367 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 367 scientific_name Homo sapiens ERS16297143 SAMEA114308141 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 368 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 368 scientific_name Homo sapiens ERS16297144 SAMEA114308142 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 369 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 369 scientific_name Homo sapiens ERS16297145 SAMEA114308143 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 37 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 37 scientific_name Homo sapiens ERS16297146 SAMEA114308144 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 370 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 370 scientific_name Homo sapiens ERS16297147 SAMEA114308145 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 371 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 371 scientific_name Homo sapiens ERS16297148 SAMEA114308146 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 372 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 372 scientific_name Homo sapiens ERS16297149 SAMEA114308147 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 373 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 373 scientific_name Homo sapiens ERS16297150 SAMEA114308148 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 374 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 374 scientific_name Homo sapiens ERS16297151 SAMEA114308149 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 375 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 375 scientific_name Homo sapiens ERS16297152 SAMEA114308150 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 376 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 376 scientific_name Homo sapiens ERS16297153 SAMEA114308151 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 377 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 377 scientific_name Homo sapiens ERS16297154 SAMEA114308152 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 378 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 378 scientific_name Homo sapiens ERS16297155 SAMEA114308153 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 379 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 379 scientific_name Homo sapiens ERS16297156 SAMEA114308154 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 38 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 38 scientific_name Homo sapiens ERS16297157 SAMEA114308155 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 380 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 380 scientific_name Homo sapiens ERS16297158 SAMEA114308156 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 381 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 381 scientific_name Homo sapiens ERS16297159 SAMEA114308157 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 382 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 382 scientific_name Homo sapiens ERS16297160 SAMEA114308158 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 383 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 383 scientific_name Homo sapiens ERS16297161 SAMEA114308159 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 384 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 384 scientific_name Homo sapiens ERS16297162 SAMEA114308160 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 385 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 385 scientific_name Homo sapiens ERS16297163 SAMEA114308161 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 386 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 386 scientific_name Homo sapiens ERS16297164 SAMEA114308162 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 387 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 387 scientific_name Homo sapiens ERS16297165 SAMEA114308163 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 388 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 388 scientific_name Homo sapiens ERS16297166 SAMEA114308164 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 389 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 389 scientific_name Homo sapiens ERS16297167 SAMEA114308165 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 39 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 39 scientific_name Homo sapiens ERS16297168 SAMEA114308166 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 390 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 390 scientific_name Homo sapiens ERS16297169 SAMEA114308167 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 391 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 391 scientific_name Homo sapiens ERS16297170 SAMEA114308168 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 392 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 392 scientific_name Homo sapiens ERS16297171 SAMEA114308169 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 393 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 393 scientific_name Homo sapiens ERS16297172 SAMEA114308170 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 394 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 394 scientific_name Homo sapiens ERS16297173 SAMEA114308171 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 395 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 395 scientific_name Homo sapiens ERS16297174 SAMEA114308172 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 396 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 396 scientific_name Homo sapiens ERS16297175 SAMEA114308173 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 397 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 397 scientific_name Homo sapiens ERS16297176 SAMEA114308174 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 398 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 398 scientific_name Homo sapiens ERS16297177 SAMEA114308175 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 399 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 399 scientific_name Homo sapiens ERS16297178 SAMEA114308176 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 4 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 4 scientific_name Homo sapiens ERS16297179 SAMEA114308177 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 40 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 40 scientific_name Homo sapiens ERS16297180 SAMEA114308178 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 400 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 400 scientific_name Homo sapiens ERS16297181 SAMEA114308179 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 401 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 401 scientific_name Homo sapiens ERS16297182 SAMEA114308180 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 402 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 402 scientific_name Homo sapiens ERS16297183 SAMEA114308181 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 403 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 403 scientific_name Homo sapiens ERS16297184 SAMEA114308182 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 404 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 404 scientific_name Homo sapiens ERS16297185 SAMEA114308183 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 405 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 405 scientific_name Homo sapiens ERS16297186 SAMEA114308184 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 406 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 406 scientific_name Homo sapiens ERS16297187 SAMEA114308185 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 407 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 407 scientific_name Homo sapiens ERS16297188 SAMEA114308186 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 408 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 408 scientific_name Homo sapiens ERS16297189 SAMEA114308187 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 409 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 409 scientific_name Homo sapiens ERS16297190 SAMEA114308188 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 41 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 41 scientific_name Homo sapiens ERS16297191 SAMEA114308189 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 410 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 410 scientific_name Homo sapiens ERS16297192 SAMEA114308190 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 411 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 411 scientific_name Homo sapiens ERS16297193 SAMEA114308191 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 412 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 412 scientific_name Homo sapiens ERS16297194 SAMEA114308192 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 413 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 413 scientific_name Homo sapiens ERS16297195 SAMEA114308193 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 414 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 414 scientific_name Homo sapiens ERS16297196 SAMEA114308194 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 415 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 415 scientific_name Homo sapiens ERS16297197 SAMEA114308195 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 416 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 416 scientific_name Homo sapiens ERS16297198 SAMEA114308196 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 417 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 417 scientific_name Homo sapiens ERS16297199 SAMEA114308197 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 418 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 418 scientific_name Homo sapiens ERS16297200 SAMEA114308198 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 419 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 419 scientific_name Homo sapiens ERS16297201 SAMEA114308199 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 42 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 42 scientific_name Homo sapiens ERS16297202 SAMEA114308200 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 420 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 420 scientific_name Homo sapiens ERS16297203 SAMEA114308201 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 421 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 421 scientific_name Homo sapiens ERS16297204 SAMEA114308202 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 422 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 422 scientific_name Homo sapiens ERS16297205 SAMEA114308203 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 423 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 423 scientific_name Homo sapiens ERS16297206 SAMEA114308204 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 424 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 424 scientific_name Homo sapiens ERS16297207 SAMEA114308205 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 425 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 425 scientific_name Homo sapiens ERS16297208 SAMEA114308206 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 426 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 426 scientific_name Homo sapiens ERS16297209 SAMEA114308207 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 427 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 427 scientific_name Homo sapiens ERS16297210 SAMEA114308208 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 428 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 428 scientific_name Homo sapiens ERS16297211 SAMEA114308209 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 429 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 429 scientific_name Homo sapiens ERS16297212 SAMEA114308210 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 43 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 43 scientific_name Homo sapiens ERS16297213 SAMEA114308211 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 430 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 430 scientific_name Homo sapiens ERS16297214 SAMEA114308212 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 431 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 431 scientific_name Homo sapiens ERS16297215 SAMEA114308213 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 432 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 432 scientific_name Homo sapiens ERS16297216 SAMEA114308214 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 433 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 433 scientific_name Homo sapiens ERS16297217 SAMEA114308215 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 434 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 434 scientific_name Homo sapiens ERS16297218 SAMEA114308216 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 435 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 435 scientific_name Homo sapiens ERS16297219 SAMEA114308217 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 436 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 436 scientific_name Homo sapiens ERS16297220 SAMEA114308218 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 437 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 437 scientific_name Homo sapiens ERS16297221 SAMEA114308219 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 438 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 438 scientific_name Homo sapiens ERS16297222 SAMEA114308220 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 439 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 439 scientific_name Homo sapiens ERS16297223 SAMEA114308221 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 44 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 44 scientific_name Homo sapiens ERS16297224 SAMEA114308222 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 440 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 440 scientific_name Homo sapiens ERS16297225 SAMEA114308223 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 441 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 441 scientific_name Homo sapiens ERS16297226 SAMEA114308224 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 442 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 442 scientific_name Homo sapiens ERS16297227 SAMEA114308225 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 443 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 443 scientific_name Homo sapiens ERS16297228 SAMEA114308226 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 444 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 444 scientific_name Homo sapiens ERS16297229 SAMEA114308227 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 445 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 445 scientific_name Homo sapiens ERS16297230 SAMEA114308228 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 446 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 446 scientific_name Homo sapiens ERS16297231 SAMEA114308229 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 447 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 447 scientific_name Homo sapiens ERS16297232 SAMEA114308230 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 448 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 448 scientific_name Homo sapiens ERS16297233 SAMEA114308231 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 449 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 449 scientific_name Homo sapiens ERS16297234 SAMEA114308232 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 45 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 45 scientific_name Homo sapiens ERS16297235 SAMEA114308233 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 450 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 450 scientific_name Homo sapiens ERS16297236 SAMEA114308234 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 451 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 451 scientific_name Homo sapiens ERS16297237 SAMEA114308235 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 452 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 452 scientific_name Homo sapiens ERS16297238 SAMEA114308236 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 453 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 453 scientific_name Homo sapiens ERS16297239 SAMEA114308237 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 454 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 454 scientific_name Homo sapiens ERS16297240 SAMEA114308238 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 455 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 455 scientific_name Homo sapiens ERS16297241 SAMEA114308239 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 456 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 456 scientific_name Homo sapiens ERS16297242 SAMEA114308240 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 457 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 457 scientific_name Homo sapiens ERS16297243 SAMEA114308241 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 458 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 458 scientific_name Homo sapiens ERS16297244 SAMEA114308242 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 459 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 459 scientific_name Homo sapiens ERS16297245 SAMEA114308243 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 46 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 46 scientific_name Homo sapiens ERS16297246 SAMEA114308244 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 460 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 460 scientific_name Homo sapiens ERS16297247 SAMEA114308245 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 461 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 461 scientific_name Homo sapiens ERS16297248 SAMEA114308246 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 462 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 462 scientific_name Homo sapiens ERS16297249 SAMEA114308247 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 463 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 463 scientific_name Homo sapiens ERS16297250 SAMEA114308248 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 464 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 464 scientific_name Homo sapiens ERS16297251 SAMEA114308249 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 465 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 465 scientific_name Homo sapiens ERS16297252 SAMEA114308250 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 466 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 466 scientific_name Homo sapiens ERS16297253 SAMEA114308251 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 467 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 467 scientific_name Homo sapiens ERS16297254 SAMEA114308252 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 468 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 468 scientific_name Homo sapiens ERS16297255 SAMEA114308253 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 469 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 469 scientific_name Homo sapiens ERS16297256 SAMEA114308254 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 47 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 47 scientific_name Homo sapiens ERS16297257 SAMEA114308255 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 470 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 470 scientific_name Homo sapiens ERS16297258 SAMEA114308256 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 471 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 471 scientific_name Homo sapiens ERS16297259 SAMEA114308257 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 472 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 472 scientific_name Homo sapiens ERS16297260 SAMEA114308258 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 473 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 473 scientific_name Homo sapiens ERS16297261 SAMEA114308259 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 474 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 474 scientific_name Homo sapiens ERS16297262 SAMEA114308260 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 475 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 475 scientific_name Homo sapiens ERS16297263 SAMEA114308261 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 476 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 476 scientific_name Homo sapiens ERS16297264 SAMEA114308262 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 477 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 477 scientific_name Homo sapiens ERS16297265 SAMEA114308263 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 478 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 478 scientific_name Homo sapiens ERS16297266 SAMEA114308264 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 479 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 479 scientific_name Homo sapiens ERS16297267 SAMEA114308265 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 48 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 48 scientific_name Homo sapiens ERS16297268 SAMEA114308266 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 480 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 480 scientific_name Homo sapiens ERS16297269 SAMEA114308267 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 481 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 481 scientific_name Homo sapiens ERS16297270 SAMEA114308268 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 482 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 482 scientific_name Homo sapiens ERS16297271 SAMEA114308269 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 483 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 483 scientific_name Homo sapiens ERS16297272 SAMEA114308270 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 484 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 484 scientific_name Homo sapiens ERS16297273 SAMEA114308271 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 485 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 485 scientific_name Homo sapiens ERS16297274 SAMEA114308272 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 486 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 486 scientific_name Homo sapiens ERS16297275 SAMEA114308273 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 487 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 487 scientific_name Homo sapiens ERS16297276 SAMEA114308274 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 488 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 488 scientific_name Homo sapiens ERS16297277 SAMEA114308275 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 489 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 489 scientific_name Homo sapiens ERS16297278 SAMEA114308276 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 49 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 49 scientific_name Homo sapiens ERS16297279 SAMEA114308277 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 490 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 490 scientific_name Homo sapiens ERS16297280 SAMEA114308278 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 491 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 491 scientific_name Homo sapiens ERS16297281 SAMEA114308279 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 492 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 492 scientific_name Homo sapiens ERS16297282 SAMEA114308280 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 493 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 493 scientific_name Homo sapiens ERS16297283 SAMEA114308281 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 494 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 494 scientific_name Homo sapiens ERS16297284 SAMEA114308282 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 495 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 495 scientific_name Homo sapiens ERS16297285 SAMEA114308283 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 496 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 496 scientific_name Homo sapiens ERS16297286 SAMEA114308284 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 497 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 497 scientific_name Homo sapiens ERS16297287 SAMEA114308285 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 498 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 498 scientific_name Homo sapiens ERS16297288 SAMEA114308286 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 499 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 499 scientific_name Homo sapiens ERS16297289 SAMEA114308287 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 5 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 5 scientific_name Homo sapiens ERS16297290 SAMEA114308288 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 50 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 50 scientific_name Homo sapiens ERS16297291 SAMEA114308289 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 500 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 500 scientific_name Homo sapiens ERS16297292 SAMEA114308290 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 51 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 51 scientific_name Homo sapiens ERS16297293 SAMEA114308291 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 52 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 52 scientific_name Homo sapiens ERS16297294 SAMEA114308292 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 53 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 53 scientific_name Homo sapiens ERS16297295 SAMEA114308293 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 54 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 54 scientific_name Homo sapiens ERS16297296 SAMEA114308294 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 55 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 55 scientific_name Homo sapiens ERS16297297 SAMEA114308295 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 56 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 56 scientific_name Homo sapiens ERS16297298 SAMEA114308296 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 57 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 57 scientific_name Homo sapiens ERS16297299 SAMEA114308297 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 58 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 58 scientific_name Homo sapiens ERS16297300 SAMEA114308298 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 59 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 59 scientific_name Homo sapiens ERS16297301 SAMEA114308299 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 6 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 6 scientific_name Homo sapiens ERS16297302 SAMEA114308300 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 60 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 60 scientific_name Homo sapiens ERS16297303 SAMEA114308301 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 61 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 61 scientific_name Homo sapiens ERS16297304 SAMEA114308302 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 62 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 62 scientific_name Homo sapiens ERS16297305 SAMEA114308303 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 63 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 63 scientific_name Homo sapiens ERS16297306 SAMEA114308304 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 64 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 64 scientific_name Homo sapiens ERS16297307 SAMEA114308305 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 65 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 65 scientific_name Homo sapiens ERS16297308 SAMEA114308306 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 66 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 66 scientific_name Homo sapiens ERS16297309 SAMEA114308307 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 67 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 67 scientific_name Homo sapiens ERS16297310 SAMEA114308308 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 68 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 68 scientific_name Homo sapiens ERS16297311 SAMEA114308309 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 69 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 69 scientific_name Homo sapiens ERS16297312 SAMEA114308310 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 7 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 7 scientific_name Homo sapiens ERS16297313 SAMEA114308311 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 70 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 70 scientific_name Homo sapiens ERS16297314 SAMEA114308312 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 71 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 71 scientific_name Homo sapiens ERS16297315 SAMEA114308313 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 72 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 72 scientific_name Homo sapiens ERS16297316 SAMEA114308314 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 73 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 73 scientific_name Homo sapiens ERS16297317 SAMEA114308315 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 74 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 74 scientific_name Homo sapiens ERS16297318 SAMEA114308316 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 75 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 75 scientific_name Homo sapiens ERS16297319 SAMEA114308317 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 76 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 76 scientific_name Homo sapiens ERS16297320 SAMEA114308318 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 77 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 77 scientific_name Homo sapiens ERS16297321 SAMEA114308319 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 78 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 78 scientific_name Homo sapiens ERS16297322 SAMEA114308320 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 79 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 79 scientific_name Homo sapiens ERS16297323 SAMEA114308321 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 8 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 8 scientific_name Homo sapiens ERS16297324 SAMEA114308322 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 80 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 80 scientific_name Homo sapiens ERS16297325 SAMEA114308323 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 81 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 81 scientific_name Homo sapiens ERS16297326 SAMEA114308324 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 82 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 82 scientific_name Homo sapiens ERS16297327 SAMEA114308325 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 83 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 83 scientific_name Homo sapiens ERS16297328 SAMEA114308326 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 84 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 84 scientific_name Homo sapiens ERS16297329 SAMEA114308327 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 85 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 85 scientific_name Homo sapiens ERS16297330 SAMEA114308328 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 86 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 86 scientific_name Homo sapiens ERS16297331 SAMEA114308329 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 87 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 87 scientific_name Homo sapiens ERS16297332 SAMEA114308330 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 88 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 88 scientific_name Homo sapiens ERS16297333 SAMEA114308331 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 89 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 89 scientific_name Homo sapiens ERS16297334 SAMEA114308332 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 9 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 9 scientific_name Homo sapiens ERS16297335 SAMEA114308333 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 90 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 90 scientific_name Homo sapiens ERS16297336 SAMEA114308334 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 91 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 91 scientific_name Homo sapiens ERS16297337 SAMEA114308335 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 92 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 92 scientific_name Homo sapiens ERS16297338 SAMEA114308336 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 93 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 93 scientific_name Homo sapiens ERS16297339 SAMEA114308337 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 94 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 94 scientific_name Homo sapiens ERS16297340 SAMEA114308338 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 95 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 95 scientific_name Homo sapiens ERS16297341 SAMEA114308339 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 96 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 96 scientific_name Homo sapiens ERS16297342 SAMEA114308340 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 97 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 97 scientific_name Homo sapiens ERS16297343 SAMEA114308341 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 98 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 98 scientific_name Homo sapiens ERS16297344 SAMEA114308342 9606 Homo sapiens Protocols: DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573). Per reaction a total DNA of 50–500 ng/ul was used. DNA samples were received from the Princess Margaret cancer center, University Health Network (UHN), Canada) (under UHN IRB protocol 01-0573).Per reaction a total DNA of 50–500 ng/ul was used. One microliter DNA template was added to a hybridization mix together with a MIP pool (final concentration of 0.04 pM per probe) in 0.85× Ampligase buffer. Mix was incubated in a thermal cycler at 98°C for 3 min, followed by 85°C for 30 min, 60°C for 60 min and 56°C for 60 min. Product was mixed with (final concentration in brackets): dNTPs (14 pM), Betaine (375 mM), NAD+ (1 mM), additional Ampligase buffer (0.5×), Ampligase (total of 1.25U) and Q5 High-Fidelity DNA Polymerase (0.4 U, New England Biolabs). All the product of the hybridization was incubated at 56°C for 5 min followed by 72°C for 5 min. Enzymatic digestion of linear probes was performed by adding Exonuclease I (8U) and Exonuclease III (50 U). Mixture was incubated at 37°C for 10 min, followed by 80°C for 20 min. Final product was amplified using NEBNext Ultra II Q5 Master Mix (New England Biolabs). Samples were pooled and concentrated using AMPure XP beads at 0.75× volumetric concentration and sequenced as abovementioned described. INSDC center name WIS Submitter Id E-MTAB-13306:Sample 99 broker name ArrayExpress collection date not collected common name human disease normal geographic location (country and/or sea) not collected isolate not applicable sample name E-MTAB-13306:Sample 99 scientific_name Homo sapiens